Strategic Acquisition Resolution Bioscience is now part of Exact Sciences, indicating potential access to broader distribution channels, cross-sell opportunities for Exact Sciences’ tumor profiling and liquid biopsy capabilities, and stronger onboarding support for large-scale clinical adoption.

Companion Diagnostics The company has developed over 50 focused panels and is actively advancing companion diagnostics to support therapeutic approvals, presenting an opportunity to partner on co-developed tests with pharma companies seeking validated biomarkers for targeted therapies.

Clinical Utility With a focus on using liquid biopsy to guide targeted therapy selection and monitor effectiveness, there is a clear sales path to oncology practices, hospitals, and labs prioritizing minimally invasive, repeatable testing for treatment management.

Partnership Network Past collaborations with LabCorp and Mirati Therapeutics demonstrate a readiness for strategic partnerships; leverage these relationships to propose expanded testing menus, referrals, and payer-ready diagnostic solutions.

Growth Indicators Revenue signals are modest but the integration with Exact Sciences and potential scale from a larger corporate ecosystem suggest opportunities to upsell platform services, data analytics, and broader test panels to existing Exact Sciences customers.